» Articles » PMID: 38581621

Zinc Deficiency Induces Hypertension by Paradoxically Amplifying Salt Sensitivity Under High Salt Intake in Mice

Overview
Publisher Springer
Specialty Nephrology
Date 2024 Apr 6
PMID 38581621
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypertension is one of the major etiologies that cause chronic kidney disease (CKD) and can exacerbate kidney dysfunction. Zinc is an essential trace element playing a role in blood pressure regulation, and zinc deficiency, a common comorbidity in patients with CKD, can cause hypertension. However, the precise mechanism underlying zinc deficiency-induced hypertension is unknown. Sodium (Na) retention due to inappropriate Na reabsorption in the renal tubule is the principal pathophysiology of hypertension. Therefore, this study aimed to investigate the association between zinc deficiency and salt sensitivity.

Methods: Adult mice were fed a zinc-adequate (ZnA) or zinc-deficient (ZnD) diet combined with/without high salt in drinking water (HS) for 4 weeks (n = 6 each). Changes in blood pressure, urinary sodium excretion, and the expressions of the proximal tubular Na transporter, Na/H exchanger 3 (NHE3), which mostly contributes to filtered Na reabsorption and the downstream Na-Cl transporter (NCC) were analyzed.

Results: Urinary Na excretion significantly increased in ZnD mice, indicating that zinc deficiency causes natriuresis. NHE3 expressions were significantly suppressed, whereas NCC was upregulated in ZnD mice. Interestingly, the combination of high salt and ZnD diet (HS-ZnD) reversed the urinary Na loss. The NCC remained activated and NHE3 expressions paradoxically increased in HS-ZnD mice compared with those fed the combination of high salt and ZnA diet. In addition, blood pressure significantly increased only in HS-ZnD mice.

Conclusion: The combination of zinc deficiency and high salt causes hypertension. Zinc is associated with salt-sensitivity, potentially through NHE3 and NCC regulation.

Citing Articles

Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease.

Yoshida Y, Takata T, Taniguchi S, Kageyama K, Fujino Y, Hanada H Biomedicines. 2025; 12(12.

PMID: 39767832 PMC: 11672997. DOI: 10.3390/biomedicines12122926.


Effects of zinc in podocytes and cortical collecting duct in vitro and Dahl salt-sensitive rats in vivo.

Bohovyk R, Kravtsova O, Levchenko V, Klemens C, Palygin O, Staruschenko A J Biol Chem. 2024; 300(10):107781.

PMID: 39276935 PMC: 11736004. DOI: 10.1016/j.jbc.2024.107781.

References
1.
Kon S, Konta T, Ichikawa K, Asahi K, Yamagata K, Fujimoto S . Association between renal function and cardiovascular and all-cause mortality in the community-based elderly population: results from the Specific Health Check and Guidance Program in Japan. Clin Exp Nephrol. 2017; 22(2):346-352. DOI: 10.1007/s10157-017-1455-0. View

2.
Marreiros C, Viegas C, Simes D . Targeting a Silent Disease: Vascular Calcification in Chronic Kidney Disease. Int J Mol Sci. 2022; 23(24). PMC: 9781141. DOI: 10.3390/ijms232416114. View

3.
Taal M, Brenner B . Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000; 57(5):1803-17. DOI: 10.1046/j.1523-1755.2000.00031.x. View

4.
Takata T, Isomoto H . Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int J Mol Sci. 2021; 22(9). PMC: 8122753. DOI: 10.3390/ijms22094374. View

5.
Cortinovis M, Ruggenenti P, Remuzzi G . Progression, Remission and Regression of Chronic Renal Diseases. Nephron. 2016; 134(1):20-4. DOI: 10.1159/000445844. View